HDAC6 and colorectal carcinoma: Considering all these premises, the aim of this paper was to evaluate the effects of the selective HDAC6 inhibitor ITF3756 in CRC cells in combination with bortezomib (BTZ), a proteasome inhibitor that promotes lipogenesis (Xu et al., 2021).